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Abstract
Spleen shows a high physiological uptake on radionuclide somatostatin receptor (SSTR) imaging studies. Autoradiography and 
immunohistochemistry studies showed that SSTRs are mainly located in the red pulp of the spleen. In this review article we will 
summarize the significance of splenic uptake in SSTR imaging studies and will also present high resolution splenic images of 
Ga-68 DOTANOC PET in which splenic distribution of the radiotracer appears to be correlating with the distribution of red pulp. 
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Anatomic and physiologic considerations of 
spleen
The spleen is a pulpy, oval shaped, dark red to blue-black 
colored, fist sized organ located in the left upper quadrant of the 
abdomen. Spleen is a highly vascular organ. It has 2 main compart-
ments, the red pulp and the white pulp, which have distinct function 
and morphology. The red pulp is a blood filter that removes foreign 
materials and damaged and aged red blood cells (RBCs) from the 
circulation. It is also a storage site for iron, RBCs, and platelets. 
White pulp surrounds the central arterioles and is composed 
of periarteriolar lymphoid sheath, the follicles, and the marginal 
zone. Spleen lacks afferent lymphatic vessels. Through efferent 
vessels lymphocytes migrate to the splenic lymph nodes. Immune 
responses to blood-borne antigens occurs in the white pulp [1]. The 
spleen is the largest secondary lymphoid organ which carries about 
one-fourth of the body’s lymphocytes [1]. 
Somatostatin and somatostatin receptors
Somatostatin (SST) is a regulatory peptide which is secreted by 
various tissues, mainly digestive system (delta cells in pancreatic 
islets, duodenum and pyloric antrum) and also nervous system 
(neuroendocrine cells). SST exhibits various neuroendocrine, gas-
trointestinal and neuromodulatory effects. SST has two biologically 
active forms; SST14 and SST28.
Major action of SST is inhibition of hormone secretion from 
the pituitary gland, the pancreas and other endocrine tissues and 
exocrine secretions in various sites [2]. SST inhibits release of 
growth hormone, prolactin, thyroid-stimulating hormone (TSH), 
and adrenocorticotropic hormone (ACTH) from the anterior pitui-
tary gland, insulin and glucagon from the pancreas and gastrin, 
vasoactive intestinal peptide, secretin and cholecystokinin from the 
gastrointestinal tract. Inhibitory effects of SST on various gastroin-
testinal functions include gastric acid secretion, gastric emptying, 
and intestinal motility. Its neuromodulatory effects are involved 
in learning, cognitive functions, locomotor activity, anxiety, and 
depression [3]. SST also exerts antiproliferative actions on normal 
and cancer cells via inducing cell cycle arrest and apoptosis and 
also takes part in immunoregulation [4–6].
SST exerts its effects through binding to SST receptor (SSTR) 
subtypes. There are 5 SSTR subtypes: SSTR1, SSTR2A and B, 
SSTR3, SSTR4 and SSTR5. SSTRs belong to the G protein coupled 
receptor family and widely expressed in normal tissues and solid 
tumors [7].
SSTR subtypes are expressed throughout the human body, in-
cluding the central nervous system, gastrointestinal tract, pancreas, 
kidney, prostate, thyroid, and most lymphatic tissues including 
gut-associated lymphatic tissue, spleen and thymus. 
Autoradiography and immunohistochemistry studies dem-
onstrated that SSTRs were mainly located in the red pulp of the 
spleen which contains diffusely distributed SSTRs [8–10]. The most 
abundant SSTR subtype in the spleen was SSTR2 (79.7%) followed 
by SSTR1 (19.6%), SSTR4 (0.6%), SSTR3 (0.1%) and SSTR5 (0.0%) 
[11]. Significantly higher expression of SST2A mRNA in the spleen 
was demonstrated by quantitative reverse transcription polymerase 
chain reaction [12]. Fluorescence immunocytochemistry revealed 
the presence of SST-positive cells in clusters inside the white pulp 
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and more dispersed within the red pulp of the spleen of both the 
rat and the chicken [13].
SSTRs have also been identified in a large number of human 
tumors, mainly in a high density in neuroendocrine tumors (NETs) 
such as pituitary adenoma, pancreatic islet cell tumor, carcinoid, 
pheochromocytoma, paraganglioma, medullary thyroid cancer, 
and small cell lung carcinoma and tumors of the nervous system 
including meningioma, neuroblastoma, and medulloblastoma [14, 
15]. The other tumors such as lymphoma, breast cancer, renal 
cell cancer, hepatocellular cancer, prostate cancer, sarcoma, and 
gastric cancer, may also express SSTRs [15].
Radionuclide SSTR imaging
Radionuclide SSTR imaging is used for the detection, localiza-
tion, staging and in follow-up of NETs. It is useful in the selection 
of patients for SSTR based therapy with cold or radiolabeled SST 
analogs [16, 17]. It helps monitoring response to treatment [18]. 
It may be used in other non-NET tumors expressing SSTRs such 
as lymphoma and in active inflammatory disorders such as sar-
coidosis [19, 20].
SSTR imaging with radiolabeled SST analogs have been used 
since late 1980s. In early studies I-123 Tyr-3-Octreotide was used 
which was later replaced by In-111 pentetreotide (Octreotide scin-
tigraphy, OctreoScan). Currently, there are new Ga-68 labeled SST 
analogs for positron emission tomography (PET) imaging [21]. I-125 
TYR(3)-octreotide was studied for hand held gamma probe tumor 
detection [22]. Tc-99m labeled SST analogs are also available but 
not commonly used [23]. 
The main SSTR subtype(s) targeted by various radiotracers are 
as follows: SSTR2 and SSTR5 by In-111 pentetreotide, SSTR2 by 
Ga-68 DOTATATE, SSTR2 and SSTR5 by Ga-68 DOTATOC, and 
SSTR2, SSTR3 and SSTR5 by Ga-68 DOTANOC. 
Conventional SSTR imaging with In-111 pentetreotide is still 
widely used in the detection of NETs. However, new Ga-68 labeled 
PET radiotracers have been increasingly used and replacing con-
ventional SSTR imaging in many centers due better properties of 
both the PET radiotracers and PET cameras over In-111 pentetreo-
tide and gamma cameras with single photon emission computed 
tomography (SPECT) imaging. Studies have shown the superiority 
of PET imaging with Ga-68 DOTA peptides over SPECT imaging 
with In-111 pentetreotide for NETs [24, 25]. 
As compared to In-111 pentetreotide imaging, PET scan with 
Ga-68 DOTA peptides detects more lesions, shows higher uptake 
in the lesions and provides shorter time of acquisition and lower 
radiation exposure [24, 26]. 
Splenic uptake on SSTR imaging studies
Spleen shows the highest physiological uptake on radionuclide 
SSTR imaging studies using any of the available radiolabeled 
SST analogs and it receives the highest radiation dose (critical 
organ). The reported radiation dosimetry results for the spleen 
using In-111 pentetreotide are 0.57 mGy/MBq (2.1 rad/mCi) in 
adults, 0.79 mGy/MBq (2.9 rad/mCi) in 15 year old children, and 
1.8 mGy/MBq (6.7 rad/mCi) in 5 year old children [27]. Splenic 
radiation dose in Ga-68 DOTANOC PET studies (without including 
CT) is 0.0725 mGy/MBq (0.269 rad/mCi) [28].
Studies have shown that SSTRs are mainly located in the red 
pulp of the spleen. However, it is not very clear that where exactly 
in red pulp SSTRs are located. Following SST administration there 
was a marked constriction of the splenic vascular bed with 50% 
decrease in blood flow which was suggested that this effect of SST 
was due to a direct action on vascular receptor sites [29]. Given high 
amount of SSTRs in the spleen, it is expected SSTRs to be located 
also on other sites in red pulp in addition to vascular structures. 
To better assess splenic involvement by SSTR positive tumors, 
intensity of the image setting should be reduced. Due to intense 
uptake in the spleen, tumors with low or moderate SSTR expression 
may be missed or seen as cold defects. Uptake in the accessory 
spleen or splenosis may cause false positive result for SSTR posi-
tive tumors [30]. Studies have reported that radiotracer uptake in 
splenosis is less than the normal splenic uptake [31, 32]. 
Spleen receives the highest mean absorbed dose during pep-
tide receptor radionuclide therapy. Hematological toxicity according 
to hemoglobin counts was moderately but significantly correlated 
with total absorbed spleen dose which supported the possibility 
that radiation exposure of the spleen affects overall hematological 
response during Lu-177 DOTATATE treatment [33]. On the other 
hand, a previous study has reported that hematological toxicity after 
peptide receptor radionuclide therapy is not related to the radiation 
dose to the spleen [34]. In patients with NET undergoing peptide 
receptor radionuclide therapy, the uptake of Ga-68 DOTATOC in 
spleen and other normal tissues was not significantly different in 
pre and post-treatment [35].
Radionuclide SSTR imaging studies should be interpreted 
cautiously for treatment response evaluation in patients who under-
went splenectomy after initial treatment. It was reported that there 
was higher uptake of Ga-68 DOTATOC in tumors and some normal 
tissues such as kidneys and adrenals after splenectomy [36].
In certain situations splenic uptake can be lower than the 
expected normal uptake. Treatment with cold SST analogs usu-
ally reduces splenic uptake of radiotracers for SSTR imaging 
[27, 37–39]. Several studies showed that treatment with cold SST 
analogs reduced the uptake in the spleen as well as in liver and 
kidneys, but it did not affect or even increased the uptake in the 
tumor [37–39]. Dörr et al. reported that liver, spleen, and kidney 
uptake were decreased during octreotide treatment but increased 
on lanreotide therapy, and tumor accumulation was intensified in 
majority of the patients [40].
Low physiological splenic uptake of Ga-68 DOTANOC has been 
reported in a newborn [41]. Authors of this case suggested that 
incomplete/immature expression of the SSTR in early life could be 
the reason for low splenic uptake. In-111 pentetreotide images of 
one of our patients who is a 7 year old child demonstrate less in-
tense uptake in the spleen as compared normal which could be 
due to treatment with SST analogs (Fig. 1). 
Spleen can be used as a reference to calculate tumor to spleen 
uptake ratio for estimation of SSTR density in tumors. Kratochwil et 
al. assessed the SSTR2 expression of the liver metastases in NET 
patients at baseline and after peptide receptor radiation therapy by 
measuring SUVmax, tumor to spleen ratio (T/S ratio), and tumor to 
liver ratio (T/L ratio) using Ga-68 DOTATOC [42]. Using the receiver 
operating characteristic curves, SUVmax was found a better met-
ric than both T/L ratio and T/S ratios as a stratification criterion in 
this study. In another study with Ga-68 DOTATATE, SUVmax and 
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tumor-to-spleen SUV ratio (SUV T/S) were used to assess for the 
early prediction of response to SST receptor-mediated radionuclide 
therapy in patients with well-differentiated NETS [43]. Percentage 
change in SUV scores after PRRT relative to baseline (DeltaSUV) 
was calculated. Delta SUV(T/S) was superior to Delta SUV (max) 
for prediction of outcome. 
On SSTR images spleen shows diffuse high uptake with mild 
heterogeneity. In various studies with Ga-68 DOTATOC, stand-
ardized uptake value (SUVmax) (mean ± standard deviation) in 
normal spleen was reported to be as 22.0 ± 10.0, 28.8 ± 12.5 and 
31.1 ± 10.9 [11, 31, 44]. SSTR PET images provide higher resolu-
tion spleen images than SSTR SPECT does (Fig. 2–4). Reducing 
intensity of the image settings helps better assess distribution 
of activity in the splenic parenchyma. On Ga-68 DOTANOC PET 
images, slightly heterogeneous distribution of activity with small 
areas showing less uptake than the rest of the parenchyma are 
likely due to vascular structures or regions of white pulp. Slightly 
more prominent uptake in the periphery of the spleen (subcapsular) 
and throughout parenchyma is likely from red pulp. 
Because of high splenic uptake, SSTR imaging, particularly with 
PET radiotracers, may be an alternative to standard radionuclide 
splenic imaging studies with Tc-99m heat damaged RBCs or Tc-99m 
Figure 2. In-111 pentetreotide posterior whole body image and 
selected transaxial CT, SPECT, and SPECT/CT fusion images of the 
spleen. Note the high physiological uptake in the spleen with slight 
heterogeneous distribution
Figure 3. Ga-68 DOTANOC whole body MIP (A), and selected 
transaxial CT, PET, and PET/CT fusion (B) images. PET images 
demonstrate physiological high uptake in the spleen. Compare the 
better image resolution of Ga-68 DOTANOC with In-111 Octreotide 
images in Figure 2. Note the slightly more prominent uptake in the 
periphery of the spleen which is likely from subcapsular red pulp. 
Areas showing less degree of uptake more centrally in the splenic 
parenchyma could be from splenic vascular structures and/or white 
pulp 
Figure 1. Four and 24 hr In-111 pentetreotide posterior whole body 
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sulfur colloid (Tc-99m SC). Standard radionuclide splenic imaging 
studies are the procedure of choice to image spleen, however, they 
have certain limitations. Tc-99m heat damaged RBC study is labo-
rious, time consuming, and requires strict sterile technique [45]. 
Insufficient or excessive damage to RBCs can also cause sub-
optimal study. Colloid scan with Tc-99m SC is less sensitive than 
selective spleen imaging in the identification of small splenic tis-
sues because intense hepatic uptake can obscure small splenic 
tissues [46]. PET images of spleen with Ga-68 DOTA peptides have 
better resolution than standard radionuclide SPECT images of the 
spleen. PET study is also quicker and easier to perform. Radiation 
dose to spleen also appears to be lower with Ga-68 DOTANOC 
PET imaging (without including CT) than with Tc-99m heat dam-
aged RBC scintigraphy [27, 28]. However, the main limitations of 
PET imaging of spleen with Ga-68 DOTA peptides are the high cost 
and limited availability of this radiotracer. 
Conclusion
Spleen shows a very high uptake in radionuclide SSTR imaging 
studies. Significance of splenic uptake on SSTR imaging stud-
ies have been summarized in this article. In addition it was noted 
that Ga-68 DOTA peptides provide high resolution images of the 
spleen which appears to be correlating with the distribution of red 
pulp. Because of high splenic uptake and excellent image quality, 
particularly with PET tracers, SSTR imaging may be an alternative 
to standard radionuclide splenic imaging studies to assess the 
spleen and detect accessory spleen and splenosis. 
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